Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final FDA Bill: Device Provisions

This article was originally published in The Gray Sheet

Executive Summary

Congress has settled on final language for the FDA Safety and Innovation Act. After Senate approval, the bill will go to the White House for President Obama’s signature.

Advertisement

Related Content

FDA To Consider Patient Input For Benefit-Risk Decisions For IDEs
FDA Draft Guidance Provides Definitions, Recommendations For Custom Devices
CDRH Officials Talk New Guidance, Post-Market Surveillance And 510(k)s At AdvaMed
Government Agencies Form Work Group To Develop Health IT Framework
Developing Health IT Framework Is Focus Government Working Group
Regulatory News In Brief
Washington Roundup, November-December 2012
CDRH Discloses Guidance Priorities For Fiscal 2013
FDA Releases Guidance Documents On PMA, 510(k) Review Times And Goals
Device Industry Expects Quicker Path To Market In Exchange For Doubling Of User Fees

Topics

Advertisement
UsernamePublicRestriction

Register

MT031330

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel